Current and future priorities for the development of optimal HIV drugs

Marco Vitoria, Ajay Rangaraj, Nathan Ford, Meg Doherty

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Purpose of reviewTo summarize global efforts to accelerate access to simpler, safer and more affordable antiretroviral drugs and how this has shaped HIV treatment policy over the last decade, and outline future priorities. Several expert consultations aimed at aligning opportunities for optimization of antiretroviral drugs have been convened by WHO in partnership with academic institutions, international agencies, innovators and manufacturers. The increased access to lifelong treatment for people living with HIV also brings about new challenges in the long-term use of antiretrovirals (ARVs).Recent findingsThe article describes the evolution of global research agenda on ARV optimization ascribing the characteristics of a target product profile, the importance of sequencing of first-line and second-line regimens, the role of programmatic data when looking at policy transition for new ARVs, inclusion of more subpopulations living with HIV, as well as the challenges in identifying what improvements can be made in an era where drugs are already safe, tolerable and efficacious.SummaryWithin a framework of evolving treatment harmonization and simplification, future therapeutic options in development must take into consideration safety and efficacy across a range of patient populations as well the mode of administration in the context of lifelong therapy.

Original languageEnglish (US)
Pages (from-to)143-149
Number of pages7
JournalCurrent opinion in HIV and AIDS
Issue number2
StatePublished - Mar 1 2019


  • antiretroviral therapy
  • fixed-dose combinations
  • integrase inhibitors
  • long-acting formulations
  • tenofovir alfenamide

ASJC Scopus subject areas

  • Immunology
  • Hematology
  • Oncology
  • Oncology(nursing)
  • Infectious Diseases
  • Virology


Dive into the research topics of 'Current and future priorities for the development of optimal HIV drugs'. Together they form a unique fingerprint.

Cite this